TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07703878: A Phase 1 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GS-1206 in Adults With Solid Tumors

Sponsor: Gilead Sciences · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 302 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07703878 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07703878 Rescue Dossier →